Literature DB >> 12354477

Prohibitin 3' untranslated region polymorphism and breast cancer risk in Australian women.

Amanda B Spurdle1, John L Hopper, Xiaoqing Chen, Margaret R E McCredie, Graham G Giles, Beth Newman, Georgia Chenevix-Trench.   

Abstract

A C to T transition within the 3' untranslated region of the prohibitin gene alters mRNA function, and an association between the T allele and an increased risk of breast cancer has been reported in North American women, specifically in those aged under 50 years with a first-degree family history of breast cancer. We did a population-based case-control study to assess whether this association existed in Australian women. We did not note such an association in our sample of 1446 patients and 786 controls (odds ratio 0.96, 95% CI 0.80-1.16; p=0.7), or in subgroups defined by age or family history, or both. Hence, our results do not lend support to the hypothesis that this polymorphism contributes to risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354477     DOI: 10.1016/S0140-6736(02)11043-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

2.  Association of 758 G/A polymorphism of 3'untranslated region of prohibitin with risk of gastric cancer.

Authors:  Fenfen Xiang; Zhenhua Ni; Yueping Zhan; Jian Xu; Rong Wu; Xiangdong Kang
Journal:  J Clin Lab Anal       Date:  2017-03-13       Impact factor: 2.352

3.  Raf family kinases: old dogs have learned new tricks.

Authors:  David Matallanas; Marc Birtwistle; David Romano; Armin Zebisch; Jens Rauch; Alexander von Kriegsheim; Walter Kolch
Journal:  Genes Cancer       Date:  2011-03

Review 4.  Prohibitin - At the crossroads of obesity-linked diabetes and cancer.

Authors:  Suresh Mishra; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

5.  Prohibitins are required for cancer cell proliferation and adhesion.

Authors:  Claudia Sievers; Gwendolyn Billig; Kathleen Gottschalk; Thomas Rudel
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

6.  Prohibitin: a potential biomarker for tissue-based detection of gastric cancer.

Authors:  Xiangdong Kang; Long Zhang; Jian Sun; Zhenhua Ni; Yanchun Ma; Xiaobo Chen; Xia Sheng; Teng Chen
Journal:  J Gastroenterol       Date:  2008-08-17       Impact factor: 7.527

7.  Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.

Authors:  Lucy R Webster; Pamela J Provan; Dinny J Graham; Karen Byth; Robert L Walker; Sean Davis; Elizabeth L Salisbury; Adrienne L Morey; Robyn L Ward; Nicholas J Hawkins; Christine L Clarke; Paul S Meltzer; Rosemary L Balleine
Journal:  Pathology       Date:  2013-12       Impact factor: 5.306

8.  3' untranslated region 1630 C>T polymorphism of prohibitin increases risk of breast cancer.

Authors:  Lin Tang; Yunzhao Zhao; Weiwei Nie; Zexing Wang; Xiaoxiang Guan
Journal:  Onco Targets Ther       Date:  2013-03-09       Impact factor: 4.147

9.  Cancer risk susceptibility loci in a Swedish population.

Authors:  Wen Liu; Xiang Jiao; Jessada Thutkawkorapin; Hovsep Mahdessian; Annika Lindblom
Journal:  Oncotarget       Date:  2017-11-25

10.  Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Axel Benner; Jan Lubiński; Rodney J Scott; Ute Hamann
Journal:  BMC Cancer       Date:  2008-04-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.